Navigation Links
Rosetta Genomics Leverages its MicroRNA Platform Technologies to Launch Plant Biotech Initiative
Date:10/27/2008

Initiates Rosetta Green, a Project Which Will Leverage Rosetta Genomics' Proprietary microRNA Technologies and Strong IP Position to Develop a Wide

Range of Plant-Based Applications The Company has Recently Secured Up to $1.5M From Private Investors, Which Will be Invested in the Project in Trenches as Certain Milestones are

Reached Rosetta has Already Identified microRNAs Correlated With Algal Oil Content

and Starch & Oil Content in Corn

REHOVOT, Israel and JERSEY CITY, New Jersey, October 27 /PRNewswire-FirstCall/ -- Rosetta Genomics Ltd (Nasdaq:ROSG), a leading developer of microRNA-based diagnostics and therapeutics, announced today it has launched Rosetta Green, a microRNA-based plant biotechnology project. Rosetta Green will leverage the extensive knowledge gained at Rosetta Genomics in microRNAs, as well as its proprietary technologies and strong IP position, to develop a wide range of plant-based applications. The company has recently completed a financing round from private investors exclusively for this project.

"Since our founding in 2000, we have maintained that small non-protein coding RNA - what we now know are microRNAs - play a critical role in many cellular processes," said Amir Avniel, CEO of Rosetta Genomics. "There is a large and growing body of evidence, including research we have been conducting in-house, pointing to the importance of microRNAs in plants and algal development, which may have potential applications in a wide range of plant-based biotech products. We feel it is critical at this point in time to explore this important field to ensure Rosetta Genomics remains at the forefront of research, development and
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Rosetta Genomics to Present at the Upcoming EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer"
2. Rosetta Genomics and the National Institute of Health (NIH) to Identify Potential MicroRNA Drug Targets for HIV
3. Rosetta Genomics Reports Second Quarter 2008 Financial Results
4. Rosetta Genomics Announces Conference Call and Webcast of Second Quarter Financial Results
5. Rosetta Genomics Completes Acquisition of Parkway Clinical Laboratories Inc.
6. Rosetta Genomics to Present at Collins Stewart Fourth Annual Growth Conference
7. Rosetta Genomics Announces Plans to Recruit a New Chief Financial Officer
8. Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development
9. Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests
10. /C O R R E C T I O N -- Rosetta Genomics Ltd/
11. Rosetta Genomics Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Look inside the new Preferred Solutions® ... lab, from fluid handling to instruments to supplies. Many ... you order. , Preferred Solutions features a full ... L/S® model for precise flow control and dispensing to ...
(Date:1/15/2014)... This webinar will focus on EMA and ... in biosimilars. , Regulatory frameworks are evolving many countries ... the complex nature of biopharmaceuticals makes the demonstration of ... challenging. Based on the specific aspects of biosimilar drug ...
(Date:1/15/2014)... 15, 2014 The Microcompetition with Foreign DNA ... One of these latent viruses is the Epstein Barr Virus ... Rheumatoid arthritis (RA) is a chronic inflammatory disease that destroys ... found that RA patients have high concentrations of EBV DNA ...
(Date:1/15/2014)... Toronto, ON (PRWEB) January 15, 2014 ... an experimental new therapy for the treatment of tinnitus. ... unique tinnitus frequency, and over a period of weeks to ... Notched Sound Therapy in two forms: Notched Music and Notched ...
Breaking Biology Technology:Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... ICLL) today announced that the Australian Therapeutic Goods,Administration ... to,prevent Japanese Encephalitis. This final decision step for ... Australian Drug Evaluation,Committee (ADEC) in December 2008. , ... Australian authorities represents the first,regulatory approval for the ...
... Aerolase Corporation, a leading manufacturer of next-generation portable ... sales increased dramatically in 2008 over 2007. The ... market helped to more than offset current economic ... record sales month for Aerolase, and 2008 overall ...
... Jan. 23 Peter T. Wilderotter, president and CEO ... following statement today in response to FDA clearance of ... is an exciting first step for Geron and for ... to advances in medical research. There has been so ...
Cached Biology Technology:Australian Authorities (TGA) First to Grant Final Product Approval for Intercell's Vaccine to Prevent Japanese Encephalitis 2Australian Authorities (TGA) First to Grant Final Product Approval for Intercell's Vaccine to Prevent Japanese Encephalitis 3Australian Authorities (TGA) First to Grant Final Product Approval for Intercell's Vaccine to Prevent Japanese Encephalitis 4Aerolase Reports Strong Sales in 2008 for Portable Aesthetic Lasers 2Aerolase Reports Strong Sales in 2008 for Portable Aesthetic Lasers 3Christopher and Dana Reeve Foundation Response to FDA Clearance of Geron's Clinical Trial 2
(Date:4/17/2014)... German . ... also provide us with a continuous stream of information about ... sit still in a car the world glides by ... Seemingly without effort, our brain calculates self-motion from this "optic ... a steady gaze during our own movements. Together with biologists ...
(Date:4/17/2014)... available in German . ... protection money demanded of him, he can expect his premises ... as fear of the consequences is enough to make restaurant ... birds, which lay their eggs in other birds, nests. If ... parasites take their revenge by destroying the entire nest. Consequently, ...
(Date:4/17/2014)... painted a stark warning on the possible effects of ... effect 32 times that of carbon dioxide. Now a ... act as fully regenerable electron acceptors which helps explain ... instead of being released to the atmosphere. However, there ... may enter into a vicious cycle to release large ...
Breaking Biology News(10 mins):How vision makes sure that little fish do not get carried away 2How vision makes sure that little fish do not get carried away 3How vision makes sure that little fish do not get carried away 4Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3Methane climate change risk suggested by proof of redox cycling of humic substances 2
... , Simon Fraser University virologist Masahiro Niikura and his doctoral ... that has discovered a new class of molecular compounds capable ... premise that too much of a good thing can be ... manipulating an enzyme that is key to how influenza replicates ...
... specialists at Florida Hospital Pepin Heart Institute and Dr. Kiran ... Florida announced they have enrolled their first patients into a ... of heart failure after ischemic injury. The therapy may ... to deploy more stem cells to the injury site. ...
... THAN SOUM, LAO PDR (February 21, 2012) The Wildlife ... endangered baby Siamese crocodiles into a local wetland in Lao ... The 19-month-old hatchlings, approximately 70 cm (27 inches) in length, ... at the Lao Zoo for eventual release into their native ...
Cached Biology News:Influenza study: Meet virus' new enemy 2New therapy for heart failure may enhance body's stem cell response at cardiovascular injury site 2New therapy for heart failure may enhance body's stem cell response at cardiovascular injury site 319 baby Siamese crocs released in Laos 2
Rabbit polyclonal to Lck (phospho Y192) ( Abpromise for all tested applications). entrezGeneID: 3932 SwissProtID: P06239...
Goat polyclonal to Ephrin B2 ( Abpromise for all tested applications). entrezGeneID: 1948 SwissProtID: P52799...
Mouse monoclonal [RL13] to LAP1 ( Abpromise for all tested applications). SwissProtID: Q96NW7...
Sheep polyclonal to Malate Dehydrogenase ( Abpromise for all tested applications). Antigen: Full length protein - Pig heart malate dehydrogenase. Entrez Gene ID: 4190 Swiss Protein ID: P...
Biology Products: